Nachrichten zur Catalent Inc. Aktie

Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings By Reuters

Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings…

Catalent reports Q1 loss, misses market expectations By Investing.com

Catalent reports Q1 loss, misses market expectations…

Catalent (CTLT) Reports Q1 Loss, Lags Revenue Estimates

Catalent (CTLT) delivered earnings and revenue surprises of -218.18% and 5.28%, respectively, for the quarter ended September 2024. Do the…

Roche comes out against clearing takeover of drug manufacturer Catalent By Reuters

Roche comes out against clearing takeover of drug manufacturer Catalent…

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings buyout By Reuters

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings buyout…

Catalent to sell New Jersey facility By Reuters

Catalent to sell New Jersey facility…

Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent

Ardena acquires Catalents Somerset, NJ facility, expanding its US presence and boosting advanced oral drug product manufacturing capabilities.…

Catalent delays filing of annual report By Reuters

Catalent delays filing of annual report…

Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent By Reuters

Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent…

CDMO executive says Novo purchase of Catalent may help competition - CTFN

…

Catalent (CTLT) Expands Its Facility Capabilities in Germany

Catalents (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical…

Global Dermal Toxicity Testing Market Size To Exceed USD 4.95 Billion By 2033 | CAGR of 8.11%

The Global Dermal Toxicity Testing Market Size was Valued at USD 2.27 Billion in 2023 and the Worldwide Dermal Toxicity…

Catalent exec sells over $76k in company stock By Investing.com

Catalent exec sells over $76k in company stock…

Catalents (CTLT) Latest Partnership to Boost Clinical Trials

Catalents (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving…

Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up

Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.…

Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings

Robbins LLP is investigating the acquisition of Catalent, Inc. (CTLT) by Novo Holdings to determine if it is in the…

Ares, Blue Owl Lead $4.8 Billion Private Debt for Catalent Deal

Ares Management Corp. and Blue Owl Capital Inc. are leading a group of private credit lenders providing $4.8 billion of…

Catalent executive sells $21,749 in company stock By Investing.com

Catalent executive sells $21,749 in company stock…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down

Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.…

Pharma Stocks: 5 Biggest Companies in 2024

The pharmaceutical industry is a major player in the life science sector, responsible for developing and manufacturing the majority of…

Novo Nordisk acquisition of Catalent production sensible, analysts say

Novo Nordisk (NYSE:NVO)’s takeover of three production sites through the acquisition of Catalent Inc (NYSE:CTLT) is a sensible move, analysts…

Novo Nordisk acquisition of Catalent production sensible, analysts say

Novo Nordisk (NYSE:NVO)’s takeover of three production sites through the acquisition of Catalent Inc (NYSE:CTLT) is a sensible move, analysts…

Catalent downgraded post Novo Nordisk acquisition deal By Investing.com

Catalent downgraded post Novo Nordisk acquisition deal…

Gummy Market to surpass $51 Bn by 2032, Says Global Market Insights Inc.

Major gummy market participants include Nestle SA, Bayer AG, Church & Dwight Co. Inc, Procter & Gamble, Unilever PLC (OLLY),…

Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?

Catalent (CTLT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…

Catalent acquisition by Novo Nordisk ‘a positive’

Catalent acquisition by Novo Nordisk ‘a positive’ - JPMorgan…

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Catalent, Inc. (NYSE – CTLT), Everbridge, Inc. (Nasdaq – EVBG), Slam Corp. (Nasdaq – SLAM), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

BALA CYNWYD, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.…

Catalent Call Options Take a Rollercoaster Ride Around Novo Deal

What could have been a quick profit from an options trade placed late Friday before Novo Holdings A/S said it…

CTLT Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Catalent to Novo Holdings

We are investigating the fairness of the sale of Catalent to Novo Holdings for $63.50 per share in cash.…

Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply

Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisks…

Catalent surges on $16.5 billion takeover by Novo Nordisk shareholder

Shares in drug manufacturer Catalent Inc (NYSE:CTLT) soared over 11% in pre-market trading as news broke that Novo Nordisk (NYSE:NVO)’s…

Novo Nordisk’s controlling shareholder buying Catalent for $16.5 billion

…

Novo Nordisk’s controlling shareholder to buy Catalent for $16.5 billion

The controlling shareholder of weight-loss drug maker Novo Nordisk on Monday said it’s buying a provider of drug manufacturing for…

Novo Holdings acquires Catalent for $16.5 billion By Investing.com

Novo Holdings acquires Catalent for $16.5 billion…

Novo Holdings to buy Catalent for $11.5 billion to expand Wegovy capacity By Reuters

Novo Holdings to buy Catalent for $11.5 billion to expand Wegovy capacity…

Novo Holdings to buy Catalent for $16.5 billion By Investing.com

Novo Holdings to buy Catalent for $16.5 billion…

Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction

Bagsværd, Denmark, 5 February 2024 – Novo Nordisk today announced that the company has agreed to acquire three fill-finish sites…

Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B

Novo Nordisk (NVO) will acquire Catalents three manufacturing sites from Novo Holdings to expand its manufacturing capacity.…

Catalents Indiana plant is filling Wegovy pens to Novo Nordisk for U.S.

Catalents Indiana plant is filling Wegovy pens to Novo Nordisk for U.S. - ceo…

Catalent, Papa Johns rise on bullish management comments By Investing.com

Catalent, Papa Johns rise on bullish management comments…

Heres Why You Should Retain Catalent (CTLT) Stock for Now

Catalents (CTLT) products and services portfolio and technology foundation raise optimism about the stock.…

Per-Encounter Medical Market is Booming and Expected to Reach USD 377.93 Billion by 2031 | Latest InsightAce Study

Companies covered in this study are Abbott, Cardinal Health, Johnson & Johnson, Medtronic, 3M, Steris, Catalent Inc., Smiths Medical Inc.,…

Catalent (CTLT) Up on Encouraging Pre-Filled Syringe Potential

Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its…

Catalent (CTLT) Preliminary Q1 Revenues Dampened by Lower Sales

Catalent (CTLT) records lower revenues in Biologics segments in its first-quarter fiscal 2024, resulting in overall soft preliminary performance.…

Catalent, Inc. (CTLT) Q1 2024 Earnings Call Transcript

…

Catalent, Inc. 2024 Q1 - Results - Earnings Call Presentation

…

Catalent doubles down on full year outlook as preliminary 1Q earnings beat estimates

Catalent shares added more than 11% after the contract drugmaker’s preliminary first quarter earnings topped expectations and it reaffirmed its full-year...…

Catalent delays quarterly filing with SEC on $700 million impairment charge By Reuters

Catalent delays quarterly filing with SEC on $700 million impairment charge…